

21 November 2017 EMA/HMPC/327107/2017 Committee on Herbal Medicinal Products (HMPC)

European Union herbal monograph on *Valeriana officinalis* L., radix and *Humulus lupulus* L., flos

Draft

Initial assessment	
Discussion in Working Party on European Union monographs and list	January 2008
(MLWP)	May 2008
	March 2009
	May 2009
Adoption by Committee on Herbal Medicinal Products (HMPC) for release	14 May 2009
for consultation	14 May 2009
End of consultation (deadline for comments)	15 September 2009
Re-discussion in MLWP	4 May 2010
Adoption by HMPC	
Monograph (EMA/HMPC/585558/2007)	
Assessment report (EMA/HMPC/215214/2008)	
List of references (EMA/HMPC/216362/2008)	6 May 2010
Overview of comments received during public consultation	
(EMA/HMPC/132077/2010)	
HMPC Opinion (EMA/HMPC/282834/2010)	
First revision	
Discussion in Working Party on European Union monographs and	January 2017
European Union list (MLWP)	March 2017
	May 2017
	July 2017
	September 2017
Adoption by Committee on Herbal Medicinal Products (HMPC) for release	21 November 2017
for consultation	21 November 2017
Start of public consultation	15 December 2017
End of consultation (deadline for comments). Comments should be	15 March 2018
provided using this <u>template</u> to <u>hmpc.secretariat@ema.europa.eu</u>	13 Maich 2016



Keywords	Herbal medicinal products; HMPC; European Union herbal monographs; well-
	established medicinal use; traditional use; Valeriana officinalis L.; Humulus
	lupulus L.; Valerianae radix; Lupuli flos; valerian root and hop strobile

BG (bulgarski): Валериана, корен/Хмел, лист CS (čeština): kozlíkový kořen/chmelová šištice DA (dansk): Baldrianrod/Humlekopper DE (Deutsch): Baldrianwurzel/Hopfenzapfen EL (elliniká): ρίζα Βαλεριανής και ἀνθος λυκίσκου EN (English): valerian Root/hop strobile ES (español): valeriana, raíz de/lúpulo, flor de ET (eesti keel): palderjanijuur/humalakäbi FI (suomi): rohtovirmajuuri, juuri / humala, kukka FR (français): valériane (racine de)/houblon (cône de) HR (hrvatski) odoljenov korijen/cvijet uzgojenog hmelja HU (magyar): Macskagyökér és Komlótoboz IT (italiano): Valeriana radice/luppolo fiore LT (lietuvių kalba): Valerijonų šaknys ir apynių spurgai	LV (latviešu valoda): Baldriāna saknes/Apiņu ziedi MT (Malti): għerq tal-valerjana u fjura tal- ħops NL (Nederlands): Valeriaanwortel/Hopbellen PL (polski): Korzeń kozłka/szyszka chmielu PT (português): valeriana, raiz/lúpulo, cone RO (română): rădăcină de valeriană şi conuri de hamei SK (slovenčina): koreň valeriány/kvet chmeľu SL (slovenščina): korenina zdravilne špajke/cvet navadnega hmelja SV (svenska): vänderot, rot / humle, blomma IS (íslenska): NO (norsk): valerianarot/humle

European Union herbal monograph on Valeriana officinalis L., radix and Humulus lupulus L., flos

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition $^{1,\,2}$

We	ll-established use	Tra	ditional use
арр	n regard to the marketing authorisation lication of Article 10a of Directive 1/83/EC		regard to the registration application of cle 16d(1) of Directive 2001/83/EC
radi	ed combinations of <i>Valeriana officinalis</i> L., x (valerian root) and <i>Humulus Iupulus</i> L., flos p strobile)	radi	d combinations of <i>Valeriana officinalis</i> L., x (valerian root) and <i>Humulus lupulus</i> L., (hop strobile)
i) H	erbal substance	i) He	erbal substance
Not	applicable	Not	applicable
	derbal preparations used in fixed abinations of	-	lerbal preparations used in fixed binations of
a)	Dry extracts of valerian root (DER 4-8:1,	Liqu	id extracts:
L)	methanol 45-51% m/m) and hop strobile (DER 3-10:1, methanol 40-51% m/m)	a)	Liquid extract (DER 1:6.3) from a mixture of valerian root-hop strobile (1:1),
b)	Dry extracts of valerian root (DER 4-7:1, ethanol 70% V/V) and hop strobile (DER 4-8:1, methanol 40% V/V)	b)	extraction solvent ethanol 40% V/V Mixture (1:1) of valerian root tincture (DER 1:10-11), extract solvent ethanol 58% V/V and hop strobile tincture (DER 1:12-13) extract solvent ethanol 65% V/V
			1 ml contains:
			460 mg <i>Valeriana officinalis</i> L., fresh root, tincture (DER 1:10). Extraction solvent: ethanol 58 % (V/V)
			460 mg <i>Humulus lupulus</i> L., fresh strobile, tincture (DER 1:12). Extraction solvent: ethanol 65 % (V/V)
		Dry	extracts:
		a)	Dry extracts of valerian root (DER 4-6:1),

¹ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal

quality guidance.

² Detailed specifications for the herbal substance shall be given by references to bibliographic sources in absence of a monograph in the European Pharmacopoeia, a national pharmacopoeia or national codex currently used officially in a Member State.

Well-established use	Traditional use
	extraction solvent water and hop strobile (DER 3-6:1), extraction solvent water
	 b) Dry extracts of valerian root (DER 5-7:1), extraction solvent methanol 45% m/m and hop strobile (DER 5-7:1), extraction solvent water
	 c) Dry extracts of valerian root (DER 4-5:1), extraction solvent ethanol 60% V/V and hop strobile (DER 5-9:1), extraction solvent water
	d) Dry extracts of valerian root (DER 4-7:1), extraction solvent methanol 45% V/V and hop strobile (DER 4-8:1), extraction solvent ethanol 40% V/V
	e) Dry extracts of valerian root (DER 3-7:1), extraction solvent ethanol 70% V/V and hop strobile (DER 4-8:1), extraction solvent ethanol 40% V/V
	f) Dry extracts of valerian root (DER 6-7:1), extraction solvent ethanol 70% V/V and hop strobile (DER 11-14:1), extraction solvent ethanol 96% V/V
	g) Dry extracts of valerian root (DER 5-8:1), extraction solvent ethanol 85% V/V and hop strobile (DER 9-11:1), extraction solvent ethanol 90% V/V

3. Pharmaceutical form

Well-established use	Traditional use
Herbal preparation in solid dosage forms for oral use.	Herbal preparation in solid or liquid dosage forms for oral use.
The pharmaceutical form should be described by the European Pharmacopoeia full standard term.	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
Herbal medicinal product for the relief of sleep	Indication 1)

Well-established use	Traditional use
disorders.	Traditional herbal medicinal product for relief of mild symptoms of mental stress.
	Indication 2)
	Traditional herbal medicinal product used to aid sleep.
	The product is a traditional herbal medicinal product for use in specified indications exclusively based on long-standing use.

4.2. Posology and method of administration

Well-established use	Traditional use
Posology	Posology
Adolescents, adults, elderly	Adolescents, adults, elderly
Single dose	Liquid extracts:
Herbal preparation	a) Liquid extract (DER 1:6.3): single dose 20
 a) Fixed combinations of 187-374 mg/28 mg - 500 mg/65 mg dry extracts of valerian root and hop strobile, respectively 1-2 doses half to one hour before bedtime, not 	ml b) Liquid extract (1:1): Indication 1: 1 ml (approximately 40 drops) in ½ glass of water 3-5 times daily
exceeding 500 mg of valerian extract. Herbal preparation	Indication 2: 2 ml (approximately 80 drops) in ½ glass of water
b) Fixed combination of 200 mg/45 mg – 350	Dry extracts:
mg/70 mg of dry extracts of valerian root and hop strobile, respectively	a) Fixed combinations of 80 mg/20 mg or 160 mg/40 mg dry extracts of valerian root and
1-2 doses half to one hour before bedtime, not	hop strobile, respectively
exceeding 500 mg of valerian extract.	Indication 1: 3 x 3 doses or 3 x 2 doses daily
The use in children below the age of 12 years is not recommended (see 4.4. 'Special warning and precautions for use').	Indication 2: 3 x 1 or 2 x 1 doses 1 hour before bedtime
Duration of use	b) Fixed combination of 187 mg/45 mg dry extracts of valerian root and hop strobile,
Because of its gradual onset of efficacy fixed	respectively
combinations of valerian root and hops are not suitable for acute interventional treatment of	Indication 1: up to 3 x 1 doses
mild nervous tension or sleep disorders. To	Indication 2: 1 dose 1 hour before
achieve an optimal treatment effect, the continued use over 4 weeks is recommended.	c) Fixed combinations of 100 mg/30 mg of dry extracts of valerian root and hop strobile,
If symptoms persist or worsen after 4 weeks of	respectively

continued use, a doctor should be consulted.

Well-established use	Traditional use
Method of administration	Indication 1: 2-3 doses daily
Oral use	Indication 2: 2 doses 1 hour before bedtime
	 d) Fixed combinations of 125 mg/25 mg of dry extracts of valerian root and hop strobile, extracts of valerian root and hop strobile, respectively.
	Indication 1: 3 x 1 doses daily
	Indication 2: 1-2 doses 1 hour before bedtime
	e1) Fixed combinations of 100 mg/24 mg - 32 mg dry extracts of valerian root and hop strobile, respectively.
	Indication 1: 3 x 2 doses daily
	Indication 2: 2 doses 1 hour before bedtime
	e2) Fixed combinations of 68 mg/16 mg of dry extracts of valerian root and hop strobile, respectively.
	Indication 1: 3 x 3 doses daily
	Indication 2: 3 doses 1 hour before bedtime.
	e3) Fixed combinations of 200 mg/ 46-68 mg of dry extracts from valerian root and hop strobile, respectively.
	Indication 1: 3 x 1 dose daily
	Indication 2: 1 or 2 doses ½ to 1 hour before bedtime.
	f) Fixed combinations of 225 mg/30 mg dry extracts of valerian root and hop strobile, respectively.
	Indication 1: 3 x 1 doses
	Indication 2: 1 and 1-2 doses 1 hour before bedtime
	g) Fixed combinations of 77 mg/18.8 mg of dry extracts of valerian root and hop strobile, respectively.
	Indication 1: 3 x 2 doses
	Indication 2: 2 doses 1 hour before bedtime
	The use in children below the age of 12 years is not recommended (see 4.4. 'Special warning

Well-established use	Traditional use
	and precautions for use').
	Duration of use
	If the symptoms persist longer than 4 weeks of continued use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use

4.3. Contraindications

Well-established use	Traditional use
Hypersensitivity to the active substances.	Hypersensitivity to the active substances.

4.4. Special warnings and precautions for use

Well-established use	Traditional use
The use of these fixed combinations is not recommended in children under 12 years of age, due to lack of adequate data.	The use of these fixed combinations is not recommended in children under 12 years of age, due to lack of adequate data.
If the symptoms worsen during the use of medicinal product, a doctor or a pharmacist should be consulted.	For extracts containing ethanol, the appropriate labelling for ethanol, taken from the "Guideline on excipients in the label and package leaflet of medicinal products for human use" must be included.
	If the symptoms worsen during the use of medicinal product, a doctor or a pharmacist should be consulted.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
None reported	None reported

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
Safety during pregnancy and lactation has not been established.	Safety during pregnancy and lactation has not been established.
As a precautionary measure, because of lack of	As a precautionary measure, because of lack of

Well-established use	Traditional use
data, use during pregnancy and lactation is not recommended.	data, use during pregnancy and lactation is not recommended.
No fertility data available.	No fertility data available.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
May impair ability to drive and use machines.	May impair ability to drive and use machines.
Affected patients should not drive or operate	Affected patients should not drive or operate
machinery.	machinery.

4.8. Undesirable effects

Well-established use	Traditional use
Gastrointestinal symptoms (e.g. nausea, abdominal cramps) and headache may occur. The frequency is not known.	Gastrointestinal symptoms (e.g. nausea, abdominal cramps) and headache may occur. The frequency is not known.
If other adverse reactions not mentioned above occur, a doctor or a pharmacist should be consulted.	If other adverse reactions not mentioned above occur, a doctor or a pharmacist should be consulted.

4.9. Overdose

Well-established use	Traditional use
No case of overdose has been reported.	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
Pharmacotherapeutic group: Hypnotics and sedatives.	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.
ATC Code: N05CM09.	
The mechanism of action not known.	
Whether hop strobile extract acts either as a mild sedative independently or as a synergist for valerian root extract, is not yet known	

5.2. Pharmacokinetic properties

Well-established use	Traditional use
No data available.	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.

5.3. Preclinical safety data

Well-established use	Traditional use
Tests on reproductive toxicity, genotoxicity and carcinogenicity of the combination of valerian root and hop strobile have not been performed.	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.
	Tests on reproductive toxicity, genotoxicity and carcinogenicity of the combination of valerian root and hop strobile have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
Not applicable	Not applicable

7. Date of compilation/last revision

21 November 2017.